# Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

> **NCT07444814** · PHASE1 · RECRUITING · sponsor: **Whitehawk Therapeutics, Inc.** · enrollment: 226 (estimated)

## Conditions studied

- Endometrial Cancer
- Ovarian Cancer
- Ovarian Cancer Metastatic
- Ovarian Cancer Metastatic Recurrent
- Non-squamous EGFR Wt NSCLC
- Platinum Resistant Ovarian Cancer
- PROC

## Interventions

- **DRUG:** HWK-007

## Key facts

- **NCT ID:** NCT07444814
- **Lead sponsor:** Whitehawk Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-19
- **Primary completion:** 2028-10
- **Final completion:** 2028-12
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07444814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07444814, "Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07444814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*